{"id":"W2991627091","doi":"10.1016/j.jtho.2019.11.004","title":"Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Servier; Berlin Mathematical School; Exelixis; Meso Scale Diagnostics; Takeda Pharmaceutical Company; AbbVie; Gilead Sciences; Takeda Oncology; University of Colorado; Boehringer Ingelheim; Ariad Pharmaceuticals; Roche; Novartis; GlaxoSmithKline; Sanofi-Aventis Deutschland; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Crizotinib; Medicine; Refractory (planetary science); Oncology; Internal medicine; Lung cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009856882,0.0001389761,0.0006792931,0.0002577073,0.00003094093,0.0000182348,0.0001234711,0.0001456672,0.00008373351],"category_scores_gemma":[0.0002652918,0.00008109232,0.0001228307,0.0001468018,0.00004533576,0.0001138837,0.00001569838,0.0005427277,0.00002199621],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003462366,"about_ca_system_score_gemma":0.0005349457,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005081875,"about_ca_topic_score_gemma":0.00007528784,"domain_scores_codex":[0.998344,0.0003382274,0.0006856916,0.0001537211,0.0002784058,0.0001999396],"domain_scores_gemma":[0.9986389,0.0005921702,0.0004286572,0.0001757792,0.00007878835,0.00008575377],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3284396,0.01164371,0.1396233,0.0004175051,0.001160662,0.004392328,0.01904109,0.0000415223,0.005063429,0.0006590667,0.002738262,0.4867795],"study_design_scores_gemma":[0.7019049,0.07812248,0.1584875,0.002215086,0.002196669,0.005336233,0.01739861,0.000154816,0.0002828606,0.0007919473,0.03254804,0.0005608253],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9901568,0.0002501352,0.000006885005,0.003887464,0.001790516,0.0008873419,0.000009154449,0.000005081704,0.003006598],"genre_scores_gemma":[0.9980378,0.00007240269,0.0002212751,0.0008525765,0.0003896377,0.00001740979,0.00000475577,0.00001406396,0.0003901083],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4862187,"threshold_uncertainty_score":0.3306849,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02598260838158858,"score_gpt":0.4525316280524112,"score_spread":0.4265490196708226,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}